Cardiac Research: Evolve II

EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)

Objective

The purpose of this study is to compare the safety and effectiveness of two drug-eluting stents in the treatment of coronary artery disease: the SYNERGYTM Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY stent) and  the PROMUS Element™ Plus Everolimus Eluting Platinum Chromium Coronary Stent System (PROMUS Element Plus stent).

The SYNERGY stent is investigational, while the PROMUS stent has been approved by the FDA.

The SYNERGY and PROMUS Element Plus stents are different in the location and type of the coating (polymer) used on the metal.  The polymer holds the drug onto the stent. The polymer on the SYNERGY stent is on the outside of the stent (side touching the artery wall), whereas, the polymer on the PROMUS Element Plus stent is on all sides of the stent (the inside and outside of the stent). Additionally, the polymer on the SYNERGY stent is bioabsorbable.  It is completely absorbed by your body within 4 months. The polymer on the PROMUS Element Plus stent is not absorbed by your body and remains permanently on the stent.

Principal Investigator(s)
Jon Robken

Clinical Trial Categories

  • Cardiac Research
Sponsor(s)
Boston Scientific
Contact
Genesis Research at 563-421-3941

Location

  • Medical Center, East Rusholme Street
    1227 East Rusholme Street
    Davenport, IA 52803
    Main: 563-421-1000

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email